Abstracts Archive - Page 754 of 2607 - ACR Meeting Abstracts

Abstract Number: 0733 • ACR Convergence 2021
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Emmanuel Maheu¹, Sandrine Soriot-Thomas², Eric Noël³, Hervé Ganry⁴, Eric Lespessailles⁵ and Bernard Cortet⁶, ¹Saint-Antoine Hospital, Paris, France, ²CHU Amiens Picardie, Amiens, France, ³Santy Orthopaedic Center, Lyon, France, ⁴Hergan Consulting 4U, Amiens, France, ⁵CH Orléans, ORLEANS, France, ⁶CHU Lille, Lille, France
Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…
Abstract Number: 0734 • ACR Convergence 2021
Primary Total Knee Arthroplasty for Knee Osteoarthritis Among Younger versus Older Individuals: Cross-sectional Study of Surgical Appropriateness and Surgeon Decision-Making
Gillian Hawker¹, Eric Bohm², Michael Dunbar³, Allyson Jones⁴, Tom Noseworthy⁵ and Deborah Marshall⁵, ¹University of Toronto, Toronto, ON, Canada, ²Concordia Hip & Knee Institute, Winnipeg, MB, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Calgary, Calgary, AB, Canada
Background/Purpose: Rising rates of total knee arthroplasty (TKA) in younger adults with knee osteoarthritis (OA) has prompted concern about surgical appropriateness. We compared patient appropriateness…
Abstract Number: 0735 • ACR Convergence 2021
Walking Ability 12 Months After Total Knee Arthroplasty for Osteoarthritis – Gap Between Expectations and Reality: The BEST Knee Cohort Study
Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: Improved ability to walk is a key driver for people with knee osteoarthritis (OA) to seek total knee arthroplasty (TKA). However, the extent to…
Abstract Number: 0736 • ACR Convergence 2021
Decrease in Prevalence of Self-Reported Anxiety or Depression in Persons with Osteoarthritis After Total Knee Arthroplasty: The BEST KNEE Cohort Study
Owen Krystia, Lauren King, Esther Waugh and Gillian Hawker, University of Toronto, Toronto, ON, Canada
Background/Purpose: While anxiety and depression are highly prevalent in persons with symptomatic knee osteoarthritis (OA), few studies have assessed the effect of treatment of knee…
Abstract Number: 0737 • ACR Convergence 2021
Enhanced Arthrocentesis of the Flexed Knee with Pneumatic Compression
Sumir Brahmbhatt¹, Ahsan Iqbal¹, Fatemeh Farshami², Maheswari Muruganandam³, Jaren Trost⁴, David Cisneros⁵, Adnan Kiani³, N. Suzanne Emil³, Sharon Nunez¹, William Hayward⁶, Philip Band⁷ and Wilmer Sibbitt³, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, MD, ³University of New Mexico, Albuquerque, NM, ⁴Optum, Albuquerque, NM, ⁵University of New Mexico School of Medicine, Albuquerque, NM, ⁶New Mexico Highlands University, Las Vegas, NM, ⁷NYU SOM, New York, NY
Background/Purpose: To explore an alternative to standard extended knee arthrocentesis using pneumatic compression of the flexed knee.Methods: Using a paired sample design, 41 consecutive effusive…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 0739 • ACR Convergence 2021
Contextual Factors Should Complete the Assessment of Functioning in Patients with Axial Spondyloarthritis (axSpA)
Uta Kiltz¹, Eerik Ahomaa², Björn Buehring¹, Xenofon Baraliakos¹, David Kiefer¹, Jaclyn-Dalisay Leicht¹ and Jürgen Braun¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²St. Franziskus-Hospital, Department of Orthopedic Surgery, Cologne, Germany
Background/Purpose: Functioning of axSpA patients (pat.) is influenced by many factors, but how contextual factors influence functioning isn’t well studied. According to the International Classification…
Abstract Number: 0740 • ACR Convergence 2021
Rheumatologists’ and Patients’ Mental Models for Treatment of RA Explain Low Rates of TTT
Betty Hsiao¹, Julie Downs², Mandy Lanyon², William Nowell³, SHILPA VENKATACHALAM⁴, Carole Wiedmeyer⁵, Jeffrey Curtis⁶, Susan Blalock⁷, Leslie Harrold⁸ and Liana Fraenkel⁹, ¹Yale-New Haven Medical Center, New Haven, CT, ²Carnegie Mellon, Pittsburgh, PA, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, New York, NY, ⁵Global Healthy Living Foundation, Nyack, NY, ⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁷Chapel Hill, Chapel Hill, NC, ⁸Corrona, LLC, Northborough, MA, ⁹Berkshire Medical Center, Lenox, MA
Background/Purpose: Fewer than 50% of patients with rheumatoid arthritis (RA) are treated using a TTT strategy. The purpose of this study was to better understand…
Abstract Number: 0741 • ACR Convergence 2021
Assessing the Relationship of Patient Global Assessment of Disease Activity and Health Related Quality of Life by SF-36 with Other Patient-Reported Outcomes in Rheumatoid Arthritis: Post Hoc Analyses of Data from Phase 3 Trials of Baricitinib
Vibeke Strand¹, Anthony Sebba², Savannah Scardo³, Amanda Quebe⁴, Liliana Zaremba-Pechmann⁵ and Peter C Taylor⁶, ¹Stanford University, Portola Valley, CA, ²Division of Rheumatology, University of South Florida, Tampa, FL, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Indanapolis, IN, ⁵HaaPACS, Schriesheim, Germany, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Improvements in patient-reported outcomes (PROs) were demonstrated in randomized controlled trials (RCTs) of baricitinib (BARI), an oral Janus kinase (JAK)1/JAK2 inhibitor, for the treatment…
Abstract Number: 0742 • ACR Convergence 2021
Googling Rheumatic Diseases: Evaluating the Reliability of Information Found on the Internet
Neha Chiruvolu¹, Muntarin Karim² and Vaneet Sandhu³, ¹UC Riverside School of Medicine, Riverside, CA, ²Loma Linda University, Redlands, CA, ³Loma Linda University Health, Loma Linda, CA
Background/Purpose: The internet is a significant source of information for health-related topics. Given the complexity of rheumatic diseases, rheumatologists may find their patients searching online…
Abstract Number: 0743 • ACR Convergence 2021
Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group
Dana DiRenzo¹, Ingrid de Groot², Helene Alexanderson³, Clifton Bingham¹, Ingrid E Lundberg⁴, Merrilee Needham⁵, Jin Kyun Park⁶, Malin Regardt³, Catherine Sarver⁷, Didem Saygin⁸, Yeong-Wook Song⁶, Lara Maxwell⁹, Dorcas Beaton¹⁰, Lisa Christopher-Stine¹ and Christopher Mecoli¹¹, ¹Johns Hopkins University, Baltimore, MD, ²patient research partner, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵Murdoch University, Perth, Australia, ⁶Seoul National University Hospital, Seoul, Republic of Korea, ⁷patient research partner, Baltimore, MD, ⁸University of Chicago, Chicago, IL, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…
Abstract Number: 0744 • ACR Convergence 2021
MDHAQ (Multidimensional Health Assessment Questionnaire) and PROMIS-29 (patient-reported Outcomes Measurement Information System) Domains for Physical Function, Pain, Fatigue, Anxiety, Depression, Sleep, and Ability to Participate Provide Virtually Identical Information
Kathryn Gibson¹, Tengfei Li², George Luta² and Theodore Pincus³, ¹Liverpool Hospital, Sydney, Australia, ²Georgetown University, Washington, DC, ³Rush University Medical Center, Chicago, IL
Background/Purpose: PROMIS-29 (patient-reported outcome measurement information system) has been extensively validated in many diseases according to standard deviations from normalized T-scores for 7 domains. It…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0746 • ACR Convergence 2021
Application of Existing Patient-Reported Outcome Measures for Telehealth Encounters: What’s Feasible?
Patricia Katz¹, Meera Subash¹, Martin Bergman² and Kaleb Michaud³, ¹University of California San Francisco, San Francisco, CA, ²Martin Jan Bergman, MD, Ridley Park, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Validated patient-reported outcome (PRO) measures play important roles in assessing and managing of patients with rheumatic diseases. However, use of these validated scales may…
Abstract Number: 0747 • ACR Convergence 2021
Understanding Heterogeneity in Patients’ Conceptualization of Treatment for Rheumatoid Arthritis: A Cluster Analysis
Betty Hsiao¹, Julie Downs², Mandy Lanyon², Leslie Harrold³, Jeffrey Curtis⁴, Susan Blalock⁵, Carole Wiedmeyer⁶, SHILPA VENKATACHALAM⁷, William Nowell⁸ and Liana Fraenkel⁹, ¹Yale-New Haven Medical Center, New Haven, CT, ²Carnegie Mellon, Pittsburgh, PA, ³Corrona, LLC, Northborough, MA, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Chapel Hill, Chapel Hill, NC, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Berkshire Medical Center, Lenox, MA
Background/Purpose: Uptake of treat to target strategies for the management of rheumatoid arthritis (RA) is low. While there are known system-related barriers to accessing treatment,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].